GGDEF-32 Trident
Enrolling By Invitation
99 years or below
All
Phase
N/A
8 participants needed
Brief description of study
The primary objective is to determine if TTFields to the brain concomitantly with RT and TMZ in the treatment of GBM patients prolongs the overall survival of patients, compared to RT and TMZ followed by TTFields and maintenance TMZ. Secondary objectives assess progression-free survival, 1 and 2 year survival rates, radiological response, adverse events, and quality of life between the two conditions. Overall survival will be measured as the time interval between randomization and date of death. Secondary objectives will be measured using time intervals between randomization and progression and MRI scans using RANO criteria.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
04 Aug 2024.
Study ID: GG852088
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
